Physician profile
Veronica Vestal
NPI 1437593100
$51,733.33
in general payments reported to CMS, 2019-2025
36 companies · $33K in 2025
The $33K reported for 2025 was more than what 95% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $948 · 2020: $698 · 2021: $2,316 · 2022: $1,011 · 2023: $303 · 2024: $13K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $45K · Food and Beverage: $2,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $44,600.00 |
| Food and Beverage | $2,160.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fennec Pharmaceuticals, INC. | $45,935.51 | 2024-2025 | Fyarro, Pedmark |
| Janssen Pharmaceuticals, INC | $768.41 | 2020-2024 | Erleada, Darzalex, Talvey |
| Amgen INC. | $578.85 | 2019-2022 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $443.52 | 2019-2022 | |
| Abbvie INC. | $420.02 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $391.05 | 2020-2023 | Opdivo, Pomalyst |
| Astrazeneca Pharmaceuticals Lp | $334.62 | 2019-2021 | |
| Lilly USA, LLC | $222.82 | 2021 | |
| Genentech USA, INC. | $211.74 | 2019-2022 | |
| Celgene Corporation | $210.99 | 2019 | |
| Genzyme Corporation | $202.30 | 2019-2023 | |
| Pbg Puerto Rico LLC | $201.47 | 2019-2022 | |
| Astellas Pharma US INC | $175.75 | 2019-2022 | |
| Pfizer INC. | $161.92 | 2019-2022 | |
| Eisai INC. | $144.56 | 2021-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $128.77 | 2019 | |
| Rigel Pharmaceuticals, INC. | $124.86 | 2022 | |
| Adc Therapeutics America, INC. | $119.97 | 2023 | |
| Springworks Therapeutics, INC. | $118.71 | 2024 | Ogsiveo |
| Merck Sharp & Dohme LLC | $111.65 | 2019-2021 | |
| Abbott Laboratories | $98.31 | 2023 | Jot Dx |
| Lantheus Medical Imaging, INC. | $71.10 | 2019-2020 | |
| Seagen INC. | $66.45 | 2019-2021 | |
| Taiho Oncology, INC. | $66.10 | 2021-2022 | |
| Puma Biotechnology, INC. | $55.94 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $49.90 | 2021 | |
| Novartis Pharmaceuticals Corporation | $46.90 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $43.12 | 2019-2020 | |
| Shire North American Group INC | $42.54 | 2019 | |
| Glaxosmithkline, LLC. | $40.22 | 2021-2025 | Jemperli |
| Gilead Sciences, INC. | $38.37 | 2022-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $29.61 | 2021 | |
| Tempus Ai, INC | $28.52 | 2025 | Xt Cdx |
| Takeda Pharmaceuticals U.S.A., INC. | $20.71 | 2020 | |
| Incyte Corporation | $17.89 | 2020 | |
| Pharmaand Gmbh | $10.16 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Vestal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.